Actively Recruiting
Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies
Led by Peking University People's Hospital · Updated on 2026-05-04
10
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the clinical characteristics and mechanism of Deucravacitinib in the treatment of idiopathic inflammatory myopathies.Detailed Description: The investigators designed a single center, open-label, prospective study. Adults with active idiopathic inflammatory myopathies will be enrolled, meeting the Bohan \& Peter Dermatomyositis/Polymyositis(DM/PM) or Rheumatology(ACR) \& European allance of associations for rheumatology(EULAR)(2017) diagnostic criteria. Deucravacitinib 6 mg once a day was administered for 6 months to explore its efficacy and safety, which could help to evaluate Deucravacitinib clinical characteristics and mechanism. Patients would be evaluated the improvement of clinical and laboratory indexes. Changes of symptoms, immune cell subsets and cytokines were monitored. Symptoms were evaluated by Visual Analogue Scale (VAS) of patient global and physician global, manual muscle testing(MMT-8), the Health Assessment Questionnaire(HAQ), Creatine kinase, Myositis Disease Activity Assessment Tool(MDAAT).
CONDITIONS
Official Title
Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults between 18 years and 75 years of age
- Diagnosis of active idiopathic inflammatory myopathies by Bohan & Peter DM/PM or ACR & EULAR 2017 criteria
- Active disease defined by MDAAT skin VAS 23 3 cm and at least 3 abnormal core indicators
- Inadequate response or intolerance to conventional treatments such as glucocorticoids or immunosuppressants
You will not qualify if you...
- Presence of other systemic autoimmune diseases
- Severe liver or kidney dysfunction
- Active infections including tuberculosis, hepatitis B, or HIV
- Pregnant or lactating women
- Prior use of JAK inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Y
Yirui Lian
CONTACT
Y
Yuhui Li
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here